Renaissance Capital logo

Bicara Therapeutics Priced, Nasdaq: BCAX

Phase 1 biotech developing a bifunctional antibody to target solid tumors.

Industry: Health Care

Latest Trade: $24.97 0.00 (0.0%)

First Day Return: +30.1%

Return from IPO: +38.7%

Industry: Health Care

We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-b signaling within the tumor microenvironment, or TME. Ficerafusp alfa directs the TGF-b inhibitor into the immediate TME through the binding of EGFR on tumor cells, which we believe will lead to durable responses and an increase in overall survival, or OS, while reducing the adverse effects typically associated with systemic TGF-b inhibition. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic, or R/M, HNSCC excluding patients associated with human papillomavirus infection, or HPV-positive patients, with oropharyngeal squamous cell carcinoma, or OPSCC, late in the fourth quarter of 2024 or early in the first quarter of 2025.
more less
IPO Data
IPO File Date 08/22/2024
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 17.5
Deal Size ($mm) $315
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 09/12/2024
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 17.5
Deal Size ($mm) $315
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Morgan Stanley
TD Cowen
more
Company Data
Headquarters Boston, MA, United States
Founded 2019
Employees at IPO 32
Website www.bicara.com

Bicara Therapeutics (BCAX) Performance